Compare Cognizant Technology Solutions Corp (CTSH) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Cytokinetics Inc — how do they compare? Cognizant Technology Solutions Corp trades at $60.2 (market cap $27.03B), while Cytokinetics Inc trades at $61.95 (market cap $8.62B). The key difference: Cognizant Technology Solutions Corp is far larger — about 3.1× Cytokinetics Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Cytokinetics Inc for 19 Days on average.
| CTSH | CYTK | |
|---|---|---|
Market Cap | $27.03B | $8.62B |
Volume | 9,883,888 | 2,594,626 |
Sector | Technology | Health |
52-Week High | $86.70 | $87.26 |
52-Week Low | $38.73 | $54.76 |
Typical Hold Time | 57 Days | 19 Days |
Enterprise Value | $28.08B | $8.72B |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $57.07, down 0.26% on the day, with a bearish technical signal from moving averages. The company reported revenue of $21.11B in 2025 with a net income margin of 10.26%, and recent quarterly earnings have mostly beaten expectations. Analysts maintain a consensus price target of $64.25, with 45.1% recommending a buy. Positive news includes AI partnerships and workplace recognitions, but cash flow trends show volatility.
CTSH presents a mixed outlook: undervalued fundamentals with a P/E of 12.88 and strong profitability support upside potential, but technical weakness and competitive IT spending pressures pose risks. The stock's performance hinges on Q3 2026 earnings results due October 29, 2026, which could validate AI-driven growth initiatives or exacerbate bearish sentiment.
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
